Finding small molecules to help restore cancer-fighting functions of mutated proteins
Discovery of small molecule mutant SMAD4-PPI inducers
This study is looking for new ways to help fight cancer by finding special medicines that can fix problems in certain genes that usually help stop tumors from growing, and it could lead to better treatments for patients with specific types of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10891463 on NIH RePORTER |
What this research studies
This research focuses on targeting specific mutations in tumor suppressor genes that hinder their ability to fight cancer. By developing small molecules that can restore the normal protein-protein interactions disrupted by these mutations, the study aims to reactivate the tumor suppressor functions. The approach involves screening a library of chemicals to identify those that can effectively induce the desired interactions, particularly using the SMAD4 protein as a model. Patients with certain cancer types may benefit from new therapies derived from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers associated with mutations in the SMAD4 tumor suppressor gene.
Not a fit: Patients whose cancers are not linked to SMAD4 mutations or those with other types of tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that restore the cancer-fighting abilities of mutated proteins in patients with specific cancers.
How similar studies have performed: Other research has shown promise in targeting protein-protein interactions in cancer therapy, suggesting that this approach could be effective.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Mo, Xiulei — Emory University
- Study coordinator: Mo, Xiulei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.